G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors

被引：0
|
作者：
Sorrentino, Jessica A.
Bisi, John E.
Roberts, Patrick J.
Strum, Jay C.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2824
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2824
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
    Bisi, John E.
    Sorrentino, Jessica A.
    Roberts, Patrick J.
    Tavares, Francis X.
    Strum, Jay C.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) : 783 - 793
  • [22] Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.
    Safonov, Anton Mikhailovich
    Bandlamudi, Chaitanya
    Selenica, Pier
    Marra, Antonio
    Ferraro, Emanuela
    Mandelker, Diana
    Solit, David B.
    Berger, Michael F.
    Norton, Larry
    Powell, Simon N.
    Shen, Ronglai
    Robson, Mark E.
    Chandarlapaty, Sarat
    Reis-Filho, Jorge S.
    Razavi, Pedram
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models
    Roberts, P. J.
    Lai, A. Y.
    Sorrentino, J. A.
    Malik, R. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models
    Sorrentino, Jessica A.
    Lai, Anne Y.
    Strum, Jay C.
    Roberts, Patrick J.
    CANCER RESEARCH, 2017, 77
  • [25] Preclinical evaluation of TQB3616, a highly potent and selective small-molecule CDK4/6 inhibitor
    Xu Zhaobing
    Hu Lihong
    Liu Yingchun
    Ding, Charles Z.
    Zhu, Xiaoyu
    Chen, Chen
    Zhu, Yusong
    Wu, Jiahu
    Wu, Dongdong
    Chen, Shuhui
    Zhang, Xiquan
    Yang, Ling
    Tian, Xin
    CANCER RESEARCH, 2018, 78 (13)
  • [26] CDK4/6 inhibition with lerociclib (G1T38) enhances response to PI3K or ERK inhibitors in high-throughput, ex vivo pancreatic PDX screens
    Dai, Bingbing
    Freed, Daniel M.
    Sorrentino, Jessica A.
    Augustine, Jithesh Jose
    Hughes, Tara G.
    Kang, Ya'an
    Roberts, Patrick J.
    Fleming, Jason B.
    Kim, Michael P.
    CANCER RESEARCH, 2019, 79 (13)
  • [27] G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy
    Roberts, P.
    He, S.
    Schvartsman, G.
    Patil, T.
    Sorrentio, J.
    Bisi, J.
    Hoyer, R.
    Schuster, S.
    Strum, J.
    Heymach, J.
    Ferrarotto, R.
    Sharpless, N.
    Shapiro, G.
    Malik, R.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S143 - S144
  • [28] G1T28-1, a novel CDK4/6 inhibitor, protects murine hematopoietic stem and progenitor cells from cytotoxic chemotherapy
    Sorrentino, Jessica A.
    He, Shenghui
    Bisi, John E.
    Roberts, Patrick J.
    Strum, Jay C.
    Sharpless, Norman E.
    CANCER RESEARCH, 2015, 75
  • [29] VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resistant advanced solid tumors
    Yap, Timothy
    Patel, Manish
    Henick, Brian
    Moore, Kathleen
    Leary, Alexandra
    Do, Doreen
    Chapman, Josh
    Zhang, Hui
    Roche, Maria
    Newberry, Kate
    Rinne, Mikael
    Juric, Dejan
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S173 - S173
  • [30] ABEMACICLIB, A SELECTIVE CDK4/6 INHIBITOR, RESTRICTS GROWTH OF PEDIATRIC GLIAL-LINEAGE TUMORS IN VITRO AND IN VIVO
    Liang, Muh-Lii
    Hsieh, Tsung-Han
    Wong, Tai-Tong
    NEURO-ONCOLOGY, 2020, 22 : 414 - 414
12345